Reuters -- Israeli drug development company BiolineRX (BLRX.TA) said on Monday that New Jersey-based Ikaria Holdings Inc had agreed to pay $285 million for a license to develop and market its BL-1040 drug for heart attack patients.
Reuters -- Israeli drug development company BiolineRX (BLRX.TA) said on Monday that New Jersey-based Ikaria Holdings Inc had agreed to pay $285 million for a license to develop and market its BL-1040 drug for heart attack patients.
